JP2009541261A - ＧｌｙＴ１輸送体において活性を有するピロリジン誘導体 - Google Patents

ＧｌｙＴ１輸送体において活性を有するピロリジン誘導体 Download PDF

Info

Publication number
JP2009541261A
JP2009541261A JP2009515863A JP2009515863A JP2009541261A JP 2009541261 A JP2009541261 A JP 2009541261A JP 2009515863 A JP2009515863 A JP 2009515863A JP 2009515863 A JP2009515863 A JP 2009515863A JP 2009541261 A JP2009541261 A JP 2009541261A
Authority
JP
Japan
Prior art keywords
methyl
pyrrolidinyl
propyl
phenyl
methyloxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009515863A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009541261A5 (enExample
Inventor
クレアー・ルイーズ・アンダートン
デイビッド・クラップハム
トレバー・レイモンド・キール
レアンダ・ジェイン・キンドン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2009541261A publication Critical patent/JP2009541261A/ja
Publication of JP2009541261A5 publication Critical patent/JP2009541261A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2009515863A 2006-06-22 2007-06-20 ＧｌｙＴ１輸送体において活性を有するピロリジン誘導体 Withdrawn JP2009541261A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0612420.0A GB0612420D0 (en) 2006-06-22 2006-06-22 Compounds
PCT/EP2007/056106 WO2007147831A1 (en) 2006-06-22 2007-06-20 Pyrrolidine derivatives having activity at the glyt1 transporter

Publications (2)

Publication Number Publication Date
JP2009541261A true JP2009541261A (ja) 2009-11-26
JP2009541261A5 JP2009541261A5 (enExample) 2010-08-05

Family

ID=36803732

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009515863A Withdrawn JP2009541261A (ja) 2006-06-22 2007-06-20 ＧｌｙＴ１輸送体において活性を有するピロリジン誘導体

Country Status (23)

Country Link
US (1) US20080070973A1 (enExample)
EP (1) EP2041082B1 (enExample)
JP (1) JP2009541261A (enExample)
KR (1) KR20090019847A (enExample)
CN (1) CN101506156A (enExample)
AR (1) AR061554A1 (enExample)
AT (1) ATE444288T1 (enExample)
AU (1) AU2007263058A1 (enExample)
BR (1) BRPI0713311A2 (enExample)
CA (1) CA2655399A1 (enExample)
CL (1) CL2007001808A1 (enExample)
CR (1) CR10498A (enExample)
DE (1) DE602007002642D1 (enExample)
EA (1) EA200970044A1 (enExample)
ES (1) ES2333918T3 (enExample)
GB (1) GB0612420D0 (enExample)
IL (1) IL195633A0 (enExample)
MA (1) MA30522B1 (enExample)
NO (1) NO20085412L (enExample)
PE (1) PE20080380A1 (enExample)
TW (1) TW200817322A (enExample)
WO (1) WO2007147831A1 (enExample)
ZA (1) ZA200810009B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20061156A1 (es) 2004-12-23 2006-12-16 Glaxo Group Ltd Derivados de benzamida como agentes inhibidores del transportador de glicina
WO2008155334A2 (en) * 2007-06-20 2008-12-24 Glaxo Group Limited Improved process of amide formation
SG186885A1 (en) 2010-06-04 2013-02-28 Albany Molecular Res Inc Glycine transporter-1 inhibitors, methods of making them, and uses thereof
US20120035156A1 (en) * 2010-08-09 2012-02-09 Daniela Alberati Combination of glyt1 compound with antipsychotics
WO2019073052A1 (en) 2017-10-13 2019-04-18 Treeway Tw001 B.V. EDARAVONE SALT

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2746959A (en) * 1953-06-02 1956-05-22 American Home Prod Diphenylethylenediamine-penicillin salt
US3145209A (en) * 1961-07-31 1964-08-18 Olin Mathieson Substituted aminophenyl-ethylamine derivatives
NZ237443A (en) * 1990-04-10 1993-11-25 Asta Medica Ag Phenalkylethylenediamine and aminomethyltetra hydroisoquinoline derivatives, platinum (ii) and (iv) complexes, methods of preparation and pharmaceutical compositions
GB0130696D0 (en) * 2001-12-21 2002-02-06 Smithkline Beecham Plc Chemical Compounds
FR2861070B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[phenyl(pyrrolidin-2-yl)methyl]benzamide et n-[(azepan-2-yl)phenylmethyl]benzamide, leur preparation et leur application en therapeutique
PE20061156A1 (es) * 2004-12-23 2006-12-16 Glaxo Group Ltd Derivados de benzamida como agentes inhibidores del transportador de glicina

Also Published As

Publication number Publication date
US20080070973A1 (en) 2008-03-20
BRPI0713311A2 (pt) 2012-03-06
GB0612420D0 (en) 2006-08-02
AU2007263058A1 (en) 2007-12-27
AR061554A1 (es) 2008-09-03
DE602007002642D1 (de) 2009-11-12
IL195633A0 (en) 2009-09-01
ES2333918T3 (es) 2010-03-02
NO20085412L (no) 2009-01-22
ZA200810009B (en) 2009-11-25
CL2007001808A1 (es) 2008-01-18
CA2655399A1 (en) 2007-12-27
EP2041082A1 (en) 2009-04-01
WO2007147831A1 (en) 2007-12-27
MA30522B1 (fr) 2009-06-01
EA200970044A1 (ru) 2009-04-28
TW200817322A (en) 2008-04-16
EP2041082B1 (en) 2009-09-30
ATE444288T1 (de) 2009-10-15
CR10498A (es) 2009-03-20
KR20090019847A (ko) 2009-02-25
PE20080380A1 (es) 2008-05-31
CN101506156A (zh) 2009-08-12

Similar Documents

Publication Publication Date Title
CN103189337A (zh) 氨基二氢化茚衍生物、包含所述氨基二氢化茚衍生物的药物组合物及其在治疗中的用途
MX2011005119A (es) Alquilciclohexileteres de dihidrotetraazabenzoazulenos.
JP2010517964A (ja) ＧｌｙＴ１トランスポーター阻害薬および神経学的および神経精神病学的障害の治療におけるその使用
JP2008525400A (ja) グリシン輸送阻害剤
JP2009530247A (ja) Ｎ−フェニル−２−オキソ−１，４−ジアザスピロ［４．５］デカ−３−エン−１−イルアセトアミド誘導体およびグリシン輸送体阻害剤としてのそれらの使用
JP2009533385A (ja) １−（２−アリール−２−オキソエチル）−３−フェニル−１，４−ジアザスピロ［４，５］デク−３−エン−２−オン誘導体およびグリシントランスポーター阻害薬としてのそれらの使用
JP2009530246A (ja) グリシントランスポーターを阻害する化合物およびその使用
JP2009541261A (ja) ＧｌｙＴ１輸送体において活性を有するピロリジン誘導体
JP2009503006A (ja) ＧｌｙＴ１トランスポーター阻害剤ならびに神経および神経精神障害の治療におけるその使用
JP2008525403A (ja) グリシントランスポーター阻害化合物としての酸素含有複素環
JP2010517963A (ja) 神経学的および神経精神病学的障害の治療におけるＧｌｙＴ１トランスポーター阻害薬としての８−オキサ−１，４−ジアザスピロ［４，５］デク−３−エン−１−イルおよび１，４，８−トリアザスピロ［４，５］デク−３−エン−１−イルアセトアミド誘導体
JP2008525398A (ja) グリシン輸送阻害剤
JP2008525399A (ja) グリシン輸送阻害剤
JP2008525402A (ja) ２−アミノ−１−フェニルエチルカルボキサミド誘導体
JP2007533715A (ja) ＧｌｙＴ１阻害剤として用いるためのモルホリニルおよびピペリジニル基を有する化合物
JP2010517959A (ja) ＧｌｙＴ１トランスポーター阻害薬および神経学的および神経精神病学的障害の治療におけるその使用
US20250145568A1 (en) Deuterated organic compounds and uses thereof
JP2007533713A (ja) Ｎ−［４−４（４−モルホリニル）フェニル］−［（４−ピペリジニル）メチル］カルボキシアミド誘導体、およびグリシントランスポーター阻害薬としてのその使用
CN102753528A (zh) 作为单胺重摄取抑制剂的二苯基氮杂*衍生物
JP2009535301A (ja) グリシントランスポーターを阻害する化合物およびその使用
JP2010515662A (ja) グリシントランスポーターＧｌｙＴ１に活性を有する化合物およびその使用
KR20030036834A (ko) 5-페닐벤질아민 화합물, 그의 제법 및 그의 합성 중간체
JP2010517962A (ja) ＧｌｙＴ１トランスポーター阻害薬および神経学的および神経精神病学的障害の治療におけるその使用
JP2010517961A (ja) ＧｌｙＴ１トランスポーター阻害薬および神経学的および神経精神病学的障害の治療におけるその使用
WO2007147836A1 (en) Glycine transporter inhibiting compounds and uses in medicine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100621

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100621

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20101227